Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Geburtshilfe und Frauenheilkunde · 01.06.2023 · 83 (06) · 694-701
DOI: 10.1055/a-1963-7511 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.06.2023. Verfasst von Sabine Matovina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's Health, University of Tübingen, Tübingen, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
ABP 980 is a biosimilar antibody to reference trastuzumab (RTZ). Aim of the following study is to confirm the similarity of ABP 980 and RTZ in terms of clinical efficacy and safety in patients with HER2-positive early breast cancer (EBC) undergoing neoadjuvant trastuzumab-containing chemotherapy in a clinical real-world situation that also includes patients receiving pertuzumab.
Methods
Patients with HER2-positive EBC, who were treated from 12/2010 to 03/2020 at the Department of Women’s Health at Tuebingen University Hospital, Germany, with at least four cycles of neoadjuvant chemotherapy (+/− pertuzumab) in combination with ABP 980 or RTZ were included in a retrospective analysis. For efficacy analysis patients achieving a pathologic complete remission (pCR = no invasive tumor in breast and lymph nodes) were compared. Safety was evaluated by comparing the number of patients with a decrease in left ventricular function (LVEF) of > 10%.
Results
124 patients were included of whom 46 (37.1%) have received ABP 980 and 77 (62.9%) were treated with RTZ. A pCR was found in 77 patients (62.1%). For patients treated with ABP 980 as compared to RTZ, there was no significant difference regarding efficacy (pCR-rates of 60.9% versus 62.8%, p = 0.829) or cardiac safety (LVEF decline in 6.5% versus 2.6%, p = 0.274).
Conclusion
Similarity of ABP 980 as compared to RTZ was confirmed in a real-world situation, including a large proportion of patients that have also received pertuzumab treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Women's Health, University of Tübingen, Tübingen, Germany.
- Institute of Pathology, Tübingen University Hospital, Tübingen, Germany.
- Department of Gynecology and Obstetrics, University Hospital of Ulm, Ulm, Germany.
ORCID-Profile: Sabine Matovina
Zitieren
APA
Matovina, S., Engler, T., Volmer, L. L., Müller, H., Grischke, E. M., Staebler, A., Hahn, M., Brucker, S. Y., & Hartkopf, A. D. (2023). Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre. Geburtshilfe und Frauenheilkunde, 83(06), 694-701. https://doi.org/10.1055/a-1963-7511
Vancouver
Matovina S, Engler T, Volmer LL, Müller H, Grischke EM, Staebler A, et al. Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre. Geburtshilfe und Frauenheilkunde. 2023;83(06):694-701. doi:10.1055/a-1963-7511
BibTeX
@article{Matovina2023,
author = {Matovina, Sabine and Engler, Tobias and Volmer, Lea-Louise and Müller, Heike and Grischke, Eva-Maria and Staebler, Annette and Hahn, Markus and Brucker, Sara Yvonne and Hartkopf, Andreas Daniel},
title = {Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre},
journal = {Geburtshilfe und Frauenheilkunde},
year = {2023},
volume = {83},
number = {06},
pages = {694--701},
doi = {10.1055/a-1963-7511}
}
EUVIMED